- Home
- BTAI vs ATRA Comparison
BTAI vs ATRA Comparison
Compare BTAI & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | ATRA |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 38.9M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BTAI | ATRA |
|---|---|---|
| Price | $1.24 | $5.18 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 2 |
| Target Price | ★ $23.25 | $5.00 |
| AVG Volume (30 Days) | ★ 1.3M | 244.1K |
| Earning Date | 03-27-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.63 | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | $141.28 | N/A |
| Revenue Next Year | $1,921.56 | N/A |
| P/E Ratio | ★ N/A | $1.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $3.92 |
| 52 Week High | $8.08 | $19.15 |
Technical Indicators
Market Signals| Indicator | BTAI | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 48.73 |
| Support Level | N/A | $4.70 |
| Resistance Level | $1.77 | $5.65 |
| Average True Range (ATR) | 0.12 | 0.48 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 15.83 | 31.85 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).